Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 37

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 37
---
 arrangement.

Unless otherwise required, we will report at least
quarterly the number of shares of common stock sold through the Sales Agent under the Sales Agreement, the net proceeds to us and the
compensation paid by us to the Sales Agent in connection with the sales of common stock.

<div align='center'>S-21</div>

In connection with the sale of common stock on
our behalf, the Sales Agent will be deemed to be an “underwriter” within the meaning of the Securities Act, and the compensation
paid to it will be deemed to be underwriting commissions or discounts. We have agreed, under the Sales Agreement, to provide indemnification
and contribution to the Sales Agent against certain civil liabilities, including liabilities under the Securities Act.

In the ordinary course of its business, the Sales
Agent and/or its affiliates may perform investment banking, broker-dealer, financial advisory or other services for us for which it may
receive separate fees.

We estimate that the total expenses from this
offering payable by us, excluding compensation payable to the Sales Agent under the Sales Agreement, will be approximately $100,000. Additionally,
pursuant to the terms of the Sales Agreement, we agreed to reimburse the Sales Agent for the reasonable fees and expenses of its legal
counsel incurred in connection with quarterly and annual bring-downs required under the Sales Agreement in an amount not to exceed $2,500
in the aggregate for each such bring-down.

The offering of common stock pursuant to the Sales
Agreement will terminate upon the earlier of (1) the sale of shares of our common stock with an aggregate offering price of $1,750,000
subject to the Sales Agreement, (2) October 29, 2028 and (3) the termination of the Sales Agreement, pursuant to its terms, by either
the Sales Agent or us.

The Company and the Sales Agent may in the future
agree to add one or more additional sales agents to the offering, in which case the Company will file a further prospectus supplement
providing the name of such additional sales agents and any other required information.

<div align='center'>S-22

LEGAL MATTERS</div>

The validity and legality of the securities offered
hereby and certain other legal matters will be passed upon for the Company by K&L Gates LLP, Charlotte, North Carolina.

<div align='center'>EXPERTS</div>

RBSM LLP, independent registered public accounting
firm, has audited our financial statements included in